C3L-03678
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 49.88364134
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- G2M_CHECKPOINT+0.340
- E2F_TARGETS+0.300
- MYC_TARGETS_V1+0.280
- APICAL_SURFACE+0.270
- SPERMATOGENESIS+0.190
- KRAS_SIGNALING_DN+0.150
- WNT_BETA_CATENIN_SIGNALING+0.120
- MITOTIC_SPINDLE+0.110
- ESTROGEN_RESPONSE_LATE+0.080
Top 10 suppressed
- PROTEIN_SECRETION-0.440
- ALLOGRAFT_REJECTION-0.370
- INFLAMMATORY_RESPONSE-0.370
- COMPLEMENT-0.360
- INTERFERON_GAMMA_RESPONSE-0.350
- ANDROGEN_RESPONSE-0.340
- IL6_JAK_STAT3_SIGNALING-0.340
- KRAS_SIGNALING_UP-0.340
- INTERFERON_ALPHA_RESPONSE-0.330
- UV_RESPONSE_DN-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 79227609-ce40-4cf9-a9eb-16732cc2bfc5 | — | — | 0.882 |
| 2 | SRR6013540 | — | cohortSQ2 | 0.879 |
| 3 | X299bbf8b.babb.4be2.a190.5411dc005aae | — | cohortA1 | 0.877 |
| 4 | BS_K3ER45RV | medulloblastoma | — | 0.874 |
| 5 | 20050169.TNBC | — | E | 0.873 |
| 6 | TCGA-77-A5G7-01B-11R-A27Q-07 | — | cohortSQ1 | 0.872 |
| 7 | TCGA-AN-A0AR-01A-11R-A00Z-07 | — | E | 0.872 |
| 8 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.862 |
| 9 | TCGA-77-6844-01A-11R-1949-07 | — | cohortSQ1 | 0.861 |
| 10 | C3N-01025 | — | cohortSQ2 | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |